

JPM Feedback from KOL call

„The KOL expects to use Caplacizumab in ALL his patients with confirmed aTTP until the ADAMTS13 activity level recovers to $>10\%$ and given the clinical profile he expects rapid uptake of Capla across the aTTP community.“

[Vertaal vanuit het Engels](#)

J.P.Morgan CAZENOVE

Europe Equity Research

Ablynx NV (ABLX BB)

Takeaways from KOL call on aTTP and the potential for Caplacizumab treatment